Regulation of renal sympathetic neurotransmission by renal α 2A-adrenoceptors is impaired in chronic renal failure

British Journal of Pharmacology

Volumn 163, Issue 2, 2011, Pages 438-446

  Hoch, Henning ^a,c   Stegbauer, Johannes ^a   Potthoff, Sebastian A ^a   Hein, Lutz ^b   Quack, Ivo ^a   Rump, Lars Christian ^a   Vonend, Oliver ^a  

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

2 adrenoceptors; 2A adrenoceptor knockout; angiotensin II; cAMP; chronic renal failure; mouse kidney; presynaptic receptors; subtotal nephrectomy; sympathetic overactivity

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ANGIOTENSIN II; CYCLIC AMP; MESSENGER RNA; NORADRENALIN;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FACILITATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY NERVE; KIDNEY PERFUSION; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRECTOMY; NERVE STIMULATION; NONHUMAN; NORADRENALIN RELEASE; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; SHAM PROCEDURE; WILD TYPE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANGIOTENSIN II; ANIMALS; CYCLIC AMP; ELECTRIC STIMULATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, KNOCKOUT; NOREPINEPHRINE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, PRESYNAPTIC; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 79954552038     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01223.x     Document Type: Article

References (42)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC), 4th ednition. Br J Pharmacol 158 (Suppl 1): S1-254.
2. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al,. (1999). Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56: 154-161. (Pubitemid 29309824)
3. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al,. (2000). Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11: 1469-1478. (Pubitemid 30483463)
4. Bakris GL, Hart P, Ritz E, (2006). Beta blockers in the management of chronic kidney disease. Kidney Int 70: 1905-1913. (Pubitemid 44863377)
5. Bohmann C, Schollmeyer P, Rump LC, (1993a). Alpha 2-autoreceptor subclassification in rat isolated kidney by use of short trains of electrical stimulation. Br J Pharmacol 108: 262-268. (Pubitemid 23007441)
6. Bohmann C, Schollmeyer P, Rump LC, (1993b). Methoxamine inhibits noradrenaline release through activation of alpha 1- and alpha 2-adrenoceptors in rat isolated kidney: involvement of purines and prostaglandins. Naunyn Schmiedebergs Arch Pharmacol 347: 273-279. (Pubitemid 23093651)
7. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, et al,. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 26: 121-136.
8. Campese VM, (2000). Neurogenic factors and hypertension in renal disease. Kidney Int 57: 2-6.
9. Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al,. (1992). Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918. (Pubitemid 23006966)
10. Cox SL, Schelb V, Trendelenburg AU, Starke K, (2000). Enhancement of noradrenaline release by angiotensin II and bradykinin in mouse atria: evidence for cross-talk between G(q/11) protein- and G(i/o) protein-coupled receptors. Br J Pharmacol 129: 1095-1102. (Pubitemid 30153965)
11. DiBona GF, (2001). Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function. Ann N Y Acad Sci 940: 395-406.
12. Gilsbach R, Roser C, Beetz N, Brede M, Hadamek K, Haubold M, et al,. (2009). Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells. Mol Pharmacol 75: 1160-1170.
13. Gilsbach R, Schneider J, Lother A, Schickinger S, Leemhuis J, Hein L, (2010). Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload. Cardiovasc Res 86: 432-442.
14. Guérin AP, Pannier B, Marchais SJ, London GM, (2008). Arterial structure and function in end-stage renal disease. Cur Hypertens Rep 2: 107-111.
15. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al,. (2002). Sympathetic nerve activity in end-stage renal disease. Circulation 106: 1974-1979. (Pubitemid 35176304)
16. Hein L, (2001). Transgenic models of alpha 2-adrenergic receptor subtype function. Rev Physiol Biochem Pharmacol 142: 161-185.
17. Hein L, (2006). Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326: 541-551. (Pubitemid 44435825)
18. Hein L, Altman JD, Kobilka BK, (1999). Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402: 181-184.
19. Klein K, Daschner M, Vogel M, Oh J, Feuerstein TJ, Schaefer F, (2005). Impaired autofeedback regulation of hypothalamic norepinephrine release in experimental uremia. J Am Soc Nephrol 16: 2081-2087. (Pubitemid 41716439)
20. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al,. (2009). Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275-1281.
21. London GM, (2000). Alterations of arterial function in end-stange renal disease. Nephron 2: 111-118. (Pubitemid 30081558)
22. Ma LJ, Fogo AB, (2003). Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 64: 350-355. (Pubitemid 36714190)
23. Olli-Lahdesmaki T, Tiger M, Vainio M, Scheinin M, Kallio J, (2004). Ligand-induced alpha2-adrenoceptor endocytosis: relationship to Gi protein activation. Biochem Biophys Res Commun 321: 226-233. (Pubitemid 39055628)
24. Pfaffl MW, Horgan GW, Dempfle L, (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
25. Rump LC, Majewski H, (1987). Modulation of norepinephrine release through alpha 1- and alpha 2-adrenoceptors in rat isolated kidney. J Cardiovasc Pharmacol 9: 500-507. (Pubitemid 17052976)
26. Rump LC, Bohmann C, Schaible U, Schultze-Seemann W, Schollmeyer PJ, (1995). Beta-adrenergic, angiotensin II, and bradykinin receptors enhance neurotransmission in human kidney. Hypertension 26: 445-451.
27. Rump LC, Amann K, Orth S, Ritz E, (2000). Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 15: 1735-1738.
28. Rump LC, Amann K, Ritz E, (2003). Sympathetic innervation of the kidney in health and disease. In:, Bolis C, (ed.). Handbook of the Autonomic Nervous System in Health and Disease. Dekker: New York, pp. 561-587.
29. Sartoria C, Leporib M, Scherrera U, (2005). Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 106: 209-220.
30. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD, (2009a). Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361: 932-934.
31. Schlaich PM, Socratous F, Hennebry S, Eikles N, Lambert EA, Straznicky N, et al,. (2009b). Sympathetic activation in chronic renal failure. J Am Soc Nephrol 20: 933-939.
32. Starke K, (2001). Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. J Neurochem 78: 685-693. (Pubitemid 32777970)
33. Starke K, Göthert M, Kilbinger H, (1989). Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69: 864-989. (Pubitemid 19184852)
34. Stegbauer J, Vonend O, Oberhauser V, Rump LC, (2003). Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J Hypertens 21: 1391-1399.
35. Stegbauer J, Vonend O, Habbel S, Quack I, Sellin L, Gross V, et al,. (2005). Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. J Hypertens 23: 1691-1698. (Pubitemid 41233429)
36. Trendelenburg AU, Meyer A, Klebroff W, Guimarães S, Starke K, (2003). Crosstalk between presynaptic angiotensin receptors, bradykinin receptors and alpha2-autoreceptors in sympathetic neurons: a study in alpha2-adrenoceptor-deficient mice. Br J Pharmacol 138: 1389-1402. (Pubitemid 36609633)
37. Vonend O, Apel T, Amann K, Sellin L, Stegbauer J, Ritz E, et al,. (2004). Modulation of gene expression by moxonidine in rats with chronic renal failure. Nephrol Dial Transplant 19: 2217-2222. (Pubitemid 39214113)
38. Vonend O, Stegbauer J, Sojka J, Habbel S, Quack I, Robaye B, et al,. (2005). Noradrenaline and extracellular nucleotide cotransmission involves activation of vasoconstrictive P2X1,3- and P2Y6-like receptors in mouse perfused kidney. Br J Pharmacol 145: 66-74. (Pubitemid 40675550)
39. Vonend O, Habbel S, Stegbauer J, Roth J, Hein L, Rump LC, (2007). Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys. Br J Pharmacl 150: 121-127. (Pubitemid 46094677)
40. Vonend O, Rump LC, Ritz E, (2008). Sympathetic overactivity-the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 21: 326-330.
41. Ye S, Zhong H, Yanamadala S, Campese VM, (2006). Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 48: 309-315. (Pubitemid 44309828)
42. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al,. (2002). Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354-1359. (Pubitemid 34260428)